CPC A61K 39/099 (2013.01) [A61K 39/0018 (2013.01); A61K 39/08 (2013.01); A61K 39/39525 (2013.01); A61P 31/04 (2018.01); C07K 14/19 (2013.01); C07K 14/235 (2013.01); C07K 14/33 (2013.01); C07K 14/34 (2013.01); C12N 15/62 (2013.01); C12N 15/66 (2013.01); C12N 15/70 (2013.01); A61K 2039/542 (2013.01); A61K 2039/6031 (2013.01); A61K 2039/622 (2013.01)] | 6 Claims |
1. A process for the preparation of a second-generation tetanus toxoid vaccine, comprising the steps of:
a) inducing an E. coli culture at OD600=0.5 by adding 0.2 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG);
b) growing the culture at 14-16° Celsius (C) for 14 to 20 hours;
c) suspending the culture in 25 mM phosphate buffer containing 200 mM sodium chloride;
d) adding 1% of (2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol) to the phosphate buffer and resuspending the culture in said phosphate buffer;
e) sonicating the culture for a period of 3 minutes (at 5 sec on/off pulse) at 4° C. on cold beads;
f) centrifuging the culture for 45 to 90 minutes;
g) collecting and purifying the supernatant using Nickel-Nitrilotriacetic acid (Ni-NTA) affinity column with an eluant; and
h) combining the eluant into a pool with contaminated bands and concentrating using centrifugal filters to isolate one or more detoxified domains of a tetanus neurotoxin (DrTeNT) heavy chains proteins.
|